User profiles for "author:Kyu Yong Cho"

Kyu Yong Cho

Hokkaido University
Verified email at med.hokudai.ac.jp
Cited by 985

[HTML][HTML] The phenotype of infiltrating macrophages influences arteriosclerotic plaque vulnerability in the carotid artery

KY Cho, H Miyoshi, S Kuroda, H Yasuda… - Journal of stroke and …, 2013 - Elsevier
Background Proinflammatory (M1) macrophages and anti-inflammatory (M2) macrophages
have been identified in atherosclerotic plaques. While these macrophages have been …

HLA-DQB1* 03: 01 as a biomarker for genetic susceptibility to bullous pemphigoid induced by DPP-4 inhibitors

H Ujiie, K Muramatsu, T Mushiroda… - The Journal of …, 2018 - pubmed.ncbi.nlm.nih.gov
HLA-DQB1*03:01 as a Biomarker for Genetic Susceptibility to Bullous Pemphigoid Induced by
DPP-4 Inhibitors HLA-DQB1*03:01 as a Biomarker for Genetic Susceptibility to Bullous …

Favorable effect of sodium–glucose cotransporter 2 inhibitor, dapagliflozin, on non‐alcoholic fatty liver disease compared with pioglitazone

KY Cho, A Nakamura, K Omori… - Journal of Diabetes …, 2021 - Wiley Online Library
Abstract Aims/Introduction Sodium–glucose cotransporter 2 inhibitors, as well as
thiazolidines, suppress nonalcoholic fatty liver disease (NAFLD); however, few comparative …

Improvement of glycaemic control and treatment satisfaction by switching from liraglutide or dulaglutide to subcutaneous semaglutide in patients with type 2 diabetes …

Y Takahashi, H Nomoto, H Yokoyama… - Diabetes, Obesity …, 2023 - Wiley Online Library
Aim To investigate the effects of switching from liraglutide or dulaglutide to once‐weekly
semaglutide on glycaemic control and treatment satisfaction in patients with type 2 diabetes …

Improvement in treatment satisfaction after switching from liraglutide to dulaglutide in patients with type 2 diabetes: a randomized controlled trial

T Takase, A Nakamura, C Yamamoto… - Journal of Diabetes …, 2019 - Wiley Online Library
Abstract Aims/Introduction We compared treatment satisfaction in type 2 diabetes patients
taking daily and weekly glucagon‐like peptide‐1 receptor agonists. Materials and Methods …

Hyponatremia can be a powerful predictor of the development of isolated ACTH deficiency associated with nivolumab treatment

KY Cho, H Miyoshi, A Nakamura, T Kurita… - Endocrine Journal, 2017 - jstage.jst.go.jp
Letter to the Editor Page 1 2017, 64 (2), 235-236 Dear Editor, The report of nivolumab-induced
hypophysitis by Okano et al. was of great interest to us [1]. We have experienced four cases of …

Lipid droplet protein PLIN1 regulates inflammatory polarity in human macrophages and is involved in atherosclerotic plaque development by promoting stable lipid …

KY Cho, H Miyoshi, A Nakamura… - … of atherosclerosis and …, 2023 - jstage.jst.go.jp
Aim: Perilipins (PLINs), peripheral lipid droplet (LD) proteins, play important roles in lipid
accumulation and maturation in adipocytes. The relationship between PLIN family proteins …

Effects of dapagliflozin and/or insulin glargine on beta cell mass and hepatic steatosis in db/db mice

K Omori, A Nakamura, H Miyoshi, K Takahashi, N Kitao… - Metabolism, 2019 - Elsevier
Objective To explore the beneficial effects of dapagliflozin and/or insulin glargine on the
pancreatic beta cell mass and hepatic steatosis in db/db mice. Methods Six-week-old db/db …

[HTML][HTML] Effect of the sodium–glucose cotransporter 2 inhibitor luseogliflozin on pancreatic beta cell mass in db/db mice of different ages

K Takahashi, A Nakamura, H Miyoshi, H Nomoto… - Scientific reports, 2018 - nature.com
To examine the effects of luseogliflozin, a sodium–glucose cotransporter 2 inhibitor, on
pancreatic beta cell mass in db/db mice of different ages. db/db mice aged 6, 10, 14 and 24 …

Successful management of a patient with active Cushing's disease complicated with coronavirus disease 2019 (COVID-19) pneumonia

A Yuno, Y Kenmotsu, Y Takahashi, H Nomoto… - Endocrine …, 2021 - jstage.jst.go.jp
We provide the details of the successful management of a patient with active Cushing's
disease complicated with coronavirus disease 2019 (COVID-19) pneumonia. The patient …